Full Text
Cost-Utility Analysis of Denosumab Versus Alendronate For Postmenopausal Osteoporosis In South Korea

Abstract

Authors

G Bae H Kwon J An J Park

Back to Volume 21, Supplemental S2
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×